Benjamin F. Edwards & Company, Inc. Beam Therapeutics Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.51 Billion
- Q1 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 384 shares of BEAM stock, worth $9,158. This represents 0.0% of its overall portfolio holdings.
Number of Shares
384
Previous 91
321.98%
Holding current value
$9,158
Previous $2,000
550.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding BEAM
# of Institutions
243Shares Held
65.6MCall Options Held
311KPut Options Held
777K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.18MShares$195 Million1.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.58MShares$181 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.71MShares$160 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.51MShares$108 Million0.7% of portfolio
-
Morgan Stanley New York, NY4.12MShares$98.3 Million0.01% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.68B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...